Table 5.
Characteristics of Adverse Events Among Patients With MDR TB Treated With Linezolid—California, 2009–2016
| Adverse Event | Severity, No. (%) | Attributed to Linezolid, No. (%) | Days Before Occurrence, Median (Range) | Linezolid Held Due to AE, No. (%) | Linezolid Discontinued Due to AE, No. (%) | Linezolid Dose Reduced Due to AE, No. (%) | Medical Management, No. (%) | Documented Resolution, No. (%) |
|---|---|---|---|---|---|---|---|---|
| Hematologic (n = 89) | N/A | 30 (34) | 46 (9–755) | 31 (35) | 9 (10) | 16 (18) | 10 (11) | 62 (70) |
| Anemia (n = 34) | Mild: 18 (53); Moderate: 10 (29); Severe: 6 (18) | 17 (50) | 37.5 (9–755) | 12 (35) | 6 (18) | 8 (24) | 8 (24) | 15 (44) |
| Leukopenia (n = 37) | N/A | 1 (3.7) | 62 (13–366) | 8 (30) | 1 (3.7) | 2 (7.4) | 1 (3.7) | 23 (85) |
| Thrombocytopenia (n = 21) | Mild: 16 (76); Moderate: 3 (14); Severe: 2 (9.5) | 10 (48) | 30 (13–30) | 8 (38) | 2 (9.5) | 6 (29) | 0 (0) | 18 (86) |
| Neutropenia (n = 7) | Mild: 5 (71); Moderate: 2 (29); Severe: 0 (0) | 2 (29) | 94 (25–379) | 3 (43) | 0 (0) | 0 (0) | 1 (14) | 6 (86) |
| Neurologic (n = 61) | N/A | 27 (44) | 119.5 (0–820) | 24 (39) | 23 (38) | 12 (20) | 25 (41) | 22 (36) |
| Symptoms or diagnosis of peripheral neuropathy (n = 34) | N/A | 20 (59) | 119.5 (24–820) | 12 (35) | 15 (44) | 7 (21) | 19 (56) | 8 (24) |
| Vision changes or optic neuropathy (n = 25) | N/A | 6 (24) | 163 (0–668) | 11 (44) | 8 (32) | 5 (20) | 5 (20) | 12 (48) |
| Other (n = 2) | N/A | 1 (50) | 24 (10–38) | 1 (50) | 0 (0) | 0 (0) | 1 (50) | 2 (100) |
Abbreviations: AE, adverse event; N/A, not available; MDR TB, multidrug-resistant tuberculosis.